Published: August 11, 2026 | Category: M&A

Talks between the two drugmakers could create the world’s fourth-largest pharmaceutical company, but face early-stage uncertainty and likely antitrust scrutiny on both sides of the Atlantic.

AstraZeneca and Bristol Myers Squibb have held early-stage merger talks that could combine the two drugmakers into a company worth roughly $400 billion, according to a report by the Financial Times. The discussions have continued for several months and could still collapse or stall before any deal is announced.

AstraZeneca’s standalone market value stands near $263 billion, while Bristol Myers Squibb is valued at about $133 billion. A combination at that scale would create the world’s fourth-largest pharmaceutical company by market capitalization.

Shares in AstraZeneca fell as much as 7% in London trading on Monday following the report, while Bristol Myers Squibb shares rose about 6% in premarket trading in New York. Neither company has confirmed the talks, and both declined to comment on the matter.

The two companies carry significant, and partly overlapping, oncology franchises. AstraZeneca’s cancer pipeline is concentrated in solid tumors, while Bristol Myers Squibb is more focused on blood cancers and cell therapies. The companies also compete in cardiovascular disease and immunology, though analysts note the broader pipelines are largely complementary rather than duplicative.

That overlap in cancer treatments is expected to draw attention from U.S. antitrust regulators, who have scrutinized concentration in oncology drug markets in prior pharmaceutical mergers. A second regulatory question sits on the other side of the Atlantic: U.K. regulators are likely to focus on whether a combined company would redomicile to the United States, a sensitive issue given that AstraZeneca completed a New York listing only six months ago.

Analysts have reacted with some skepticism to the scale and logic of a tie-up this large, with several describing themselves as caught off guard by the report given the regulatory hurdles a deal of this size would face in both jurisdictions.

The talks, if they proceed, would rank among the largest pharmaceutical mergers on record and would reshape competitive dynamics in oncology just as both companies compete for share in a fast-growing segment of the drug market. For now, the outcome remains open: early-stage talks of this kind frequently do not result in a signed agreement.